Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Archives of Gynecology and Obstetrics
Erschienen in: Archives of Gynecology and Obstetrics 4/2015

01.10.2015 | Gynecologic Oncology

Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer

verfasst von: Li-ying Zhang, Pei-ling Li, Tian-zhen Wang, Xin-chen Zhang

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

DNA methylation is an important epigenetic modification that is frequently altered in cancer. Recent reports showed that the level of 5-hydroxymethylcytosine (5-hmC) was altered in various types of cancers. The influence of DNA methylation in epithelial ovarian cancer (EOC) is not fully understood. Therefore, the aim of the present study was to investigate factors involved in DNA demethylation in EOC compared with normal ovarian tissues.

Methods

We examined the expression of 5-hmC, 5-mC, and TET2 by immunohistochemistry in 130 cases of EOC and 40 cases of normal ovarian tissues. We assessed the prognostic values of 5-hmC, 5-mC, and TET2 in clinical outcome of EOC.

Results

We discovered a significant decrease in 5-hmC and TET2 expression in EOC compared with normal ovarian tissues. In contrast, there was a significant increase in 5-mC expression in EOC compared with normal ovarian tissues. The expression of 5-hmC, 5-mC, and TET2 correlated with pathologic stage, tumor grading, lymph node metastasis, and vascular thrombosis. Furthermore, decreased level of 5-hmC predicts poor prognosis of EOC patients. The expression of 5-hmC was an independent prognostic factor for overall survival of EOC patients.

Conclusions

The data suggest that loss of 5-hmC is an epigenetic event of EOC, and the expression of 5-hmC could serve as a prognostic factor for EOC.
Literatur
1.
Arikan SK, Kasap B, Yetimalar H, Yildiz A, Sakarya DK, Tatar S (2014) Impact of Prognostic Factors on Survival Rates in Patients with Ovarian Carcinoma. Asian Pac J Cancer Prev 15:6087–6094CrossRefPubMed
2.
Rai Bhavana, Bansal Anshuma, Patel Firuza Darius, Sharma Suresh Chander (2014) Radiotherapy for ovarian cancers-redefining the role. Asian Pac J Cancer Prev 15:4759–4763CrossRefPubMed
3.
Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S (2013) Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors. Arch Gynecol Obstet 288(6):1377–1383PubMedCentralCrossRefPubMed
4.
He SY, Shen HW, Xu L, Li XL, Yao SZ (2012) Successful management of mucinous ovarian cancer by conservative surgery in week 6 of pregnancy: case report and literature review. Arch Gynecol Obstet 286(4):989–993PubMedCentralCrossRefPubMed
5.
Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18:19–32CrossRef
6.
Conteduca V, Kopf B, Burgio SL, Bianchi E, Amadori D, De Giorgi U (2014) The emerging role of anti-angiogenic therapy in ovarian cancer (Review). Int J ncol 44:1417–1424
7.
YiChen Wu, Ling ZhiQiang (2014) The role of TET family proteins and 5-hydroxymethylcytosine in human tumors. Histol Histopathol 29:991–997
8.
9.
Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19:698–711CrossRefPubMed
10.
11.
12.
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935PubMedCentralCrossRefPubMed
13.
14.
Münzel M, Globisch D, Carell T (2011) 5-Hydroxymethylcytosine, the sixth base of the genome. Angew Chem Int Ed Engl 50:6460–6468CrossRefPubMed
15.
Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Münzel M, Müller M, Pfaffeneder T, Hackner B, Feiden W, Schüller U, Carell T, Kretzschmar HA (2012) Low values of 5-hydroxymethylcytosine (5hmC), the ‘sixth base’, are associated with anaplasia in human brain tumors. Int J Cancer 131:1577–1590CrossRefPubMed
16.
17.
Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S (2011) Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2:627–637PubMedCentralPubMed
18.
19.
Iyer LM, Thiliani M, Rao A, Aravind L (2009) Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8:1698–1710PubMedCentralCrossRefPubMed
20.
Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y (2013) Tumor development is associated with decrease of TET gene expression and 5-methlcytosine hydroxylation. Oncogene 32:663–669PubMedCentralCrossRefPubMed
21.
Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, Zheng L, Zhang H, Huang S, Min J, Nicholson T, Chen T, Xu G, Shi Y, Zhang K, Shi YG (2011) Genome-wide regulation of 5 hmC, 5 mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 42:451–464PubMedCentralCrossRefPubMed
22.
Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG (2012) Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150:1135–1146PubMedCentralCrossRefPubMed
23.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17–30PubMedCentralCrossRefPubMed
24.
Gambichler T, Sand M, Skrygan M (2013) Loss of 5- hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res 23:218–220CrossRefPubMed
25.
Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M, Sato Y (2013) In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci 104:1705–1710CrossRefPubMed
Metadaten
Titel
Prognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer
verfasst von
Li-ying Zhang
Pei-ling Li
Tian-zhen Wang
Xin-chen Zhang
Publikationsdatum
01.10.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 4/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3704-3

Weitere Artikel der Ausgabe 4/2015

Archives of Gynecology and Obstetrics 4/2015 Zur Ausgabe

Gynecologic Oncology

The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma

Review

Hysterectomy in very obese and morbidly obese patients: a systematic review with cumulative analysis of comparative studies

General Gynecology

Screening occult anal sphincter injuries in primigravid women after vaginal delivery with transperineal use of vaginal probe: a prospective, randomized controlled trial

General Gynecology

The role of ovarian fossa evaluation in patients with ovarian endometriosis

Maternal-Fetal Medicine

Adhesions at repeat cesarean delivery: is there a personal impact?

General Gynecology

Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise